Sam Brusco, Associate Editor05.16.24
Anumana, an artificial intelligence (AI)-driven health technology firm and nference portfolio company, has appointed Harry S. Palmin as its new chief financial officer (CFO). Palmin also joins nference as CFO, Ventures.
Palmin’s over 25-year career includes a stint as CFO of Acer Therapeutics, where he played a key role in its acquisition by Zevra Therapeutics. Before his role at Acer, Palmin worked in multiple executive positions at Novelos Therapeutics, where he helped transform the company from the conceptual stage to a public oncology and infectious disease development entity.
“Harry is a highly skilled and accomplished executive with a proven track record in building successful companies in the life sciences industry,” said Maulik Nanavaty, CEO of Anumana. “I am thrilled to welcome Harry to Anumana at an exciting time for the company, where we are making tremendous progress in pipeline development and commercial traction. I look forward to partnering with him through our next phase of growth.”
“Anumana is one of the most innovative companies in healthcare technology and it is an honor to be joining the organization at such a pivotal time in its growth,” added Palmin. “The progress Anumana has accomplished in just three years since its founding and the potential impact that Anumana’s AI technology platform can make on patient outcomes are inspiring. I am excited to be part of the team and the mission to use pioneering AI technology to unlock the electrical language of the heart and improve patient care.”
Anumana’s other algorithms in development include breakthrough device designated applications for pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. The company also has partnerships with pharmaceutical companies to develop and commercialize algoithms in its pipeline.
The company also received approval for two Category III CPT codes from the American Medical Association in 2022.
Palmin’s over 25-year career includes a stint as CFO of Acer Therapeutics, where he played a key role in its acquisition by Zevra Therapeutics. Before his role at Acer, Palmin worked in multiple executive positions at Novelos Therapeutics, where he helped transform the company from the conceptual stage to a public oncology and infectious disease development entity.
“Harry is a highly skilled and accomplished executive with a proven track record in building successful companies in the life sciences industry,” said Maulik Nanavaty, CEO of Anumana. “I am thrilled to welcome Harry to Anumana at an exciting time for the company, where we are making tremendous progress in pipeline development and commercial traction. I look forward to partnering with him through our next phase of growth.”
“Anumana is one of the most innovative companies in healthcare technology and it is an honor to be joining the organization at such a pivotal time in its growth,” added Palmin. “The progress Anumana has accomplished in just three years since its founding and the potential impact that Anumana’s AI technology platform can make on patient outcomes are inspiring. I am excited to be part of the team and the mission to use pioneering AI technology to unlock the electrical language of the heart and improve patient care.”
More about Anumana
The company’s software-as-a-medical-device (SaMD) ECG-AI platform helps identify hidden cardiovascular diseases from standard ECGs at the point of care. Its lead ECG-AI LEF algorithm recently earned FDA clearance for detecting low ejection fraction, a commonly undiagnosed heart failure indicator.Anumana’s other algorithms in development include breakthrough device designated applications for pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. The company also has partnerships with pharmaceutical companies to develop and commercialize algoithms in its pipeline.
The company also received approval for two Category III CPT codes from the American Medical Association in 2022.